PTX Target Price Revision – H.C Wainwright & Co
November 28, 2019 AUTHOR – enouvoteam
News 0
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The drivers to our valuation chance include: (1) adjustment to base year; (2) adjustment to exchange rate (U.S.to AUD 1.47434 on 11/26/19); and (3) lowering our discount rate from 30% to 25%, which is still higher than our usual 15% forthe majority of companies under our coverage list to account for the early stage nature of Prescient’s assets.
Click here to read the full report (report/PDF Download)
Related Posts
RECENT POSTS
Categories
- Article (106)
- Media (9)
- News (301)
- Uncategorized (1)
- Webcast Video (7)
Tags
AusBiz Biotech Dispatch BioWorld CGT Live Global Victoria Investing Kalkine Kalkine Media Market Herald Market Open Mirage News National Tribune Pitt Street Research Port Jackson Securities Prescient Therapeutics Proactive Investors Reach Markets Share Cafe ShareCafe Smallcaps Small Caps Stockhead Sub11 Switzer TechKnow Invest Roadshow The Australian The Australian Business Review The Market Herald The Sentiment Yahoo Finance